Traditional pharmacological methods of rational drug discovery investigate the target proteins' interaction sites in their native, biologically active state.

Novel methods act at the DNA level.
Sibylla follows an alternative approach, identifying small molecules that bind to pockets in the folding intermediate states, eventually preventing protein folding and leading the protein to degradation. This new class of pockets disappears in the native state, which is why Sibylla's technology enables targeting and degrading proteins that have been so far considered undruggable.